Veeva Summit presents innovations in AI and data that drive the agent-based commercial model. Oct 29, 2026, 11:02 ET AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, UCB, and other companies will showcase new approaches for connected customer engagement, agent-based MLR processes, and medical impact Barcelona, Spain, October 29, 2026 /PRNewswire/ - Veeva Systems (NYSE: VEEV) announced today that executives from AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, and UCB are among the speakers who will share strategies to drive commercial and medical excellence at the Veeva Commercial Summit, Europe, which will take place in Copenhagen, Denmark, on November 18 and 19. Attendees will discover how AI, tailored to the specific needs of the industry, enables sales, marketing, and medical teams to improve customer engagement, gain valuable insights, and accelerate content delivery while complying with current regulations. Veeva will show how both in-person and digital interactions can be transformed into commercial evidence, helping biopharmaceutical companies better understand the needs of healthcare professionals and patients, as well as improve treatment outcomes. As one of the largest gatherings of life sciences industry leaders in Europe, the Veeva Commercial Summit brings together more than 1,200 industry experts. The event will feature more than 100 sessions focused on customer success stories and AI innovations through Commercial Cloud and Data Cloud, including: Unlocking new capabilities with an agent-based commercial model * Grünenthal and Roche expand customer engagement with agents to deliver integrated experiences to healthcare professionals in in-person, digital, and event settings * GSK and other leading biopharmaceutical companies offer healthcare professionals a smarter, more personalized experience through agent-based customer relationship management (CRM) * BeOne Medicines leverages insights gained from conversational AI on brand websites to identify and address barriers to treatment for both healthcare professionals and patients * Bristol Myers Squibb accelerates promotional content approval and increases productivity with agent-based MLR Building the data foundation for AI * AstraZeneca leverages healthcare professional access data to improve field targeting and drive sales growth * Bayer and Servier create a reliable global data foundation to scale artificial intelligence use and enable better decision-making across markets Achieving greater medical impact to improve patient outcomes * Biogen, UCB, and another leading biopharmaceutical company that transforms medical insights into concrete actions to improve decision-making and patient outcomes * Bayer, Novo, and One MSL discuss how healthcare professionals' growing use of artificial intelligence is transforming scientific engagement strategies "The pace of innovation in the life sciences industry is accelerating, and artificial intelligence is creating new opportunities for more meaningful and timely engagement with healthcare professionals and patients," said Chris Moore, president of Veeva Europe. "Veeva Summit brings together a community of leaders to share knowledge and ideas as the industry moves toward an agent-based commercial model." The event is open exclusively to life sciences industry professionals, who can register at veeva.com/eu/Summit. About Veeva Systems Veeva offers the life sciences industry cloud with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechnology companies. As a public benefit corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu. Forward-looking statements by Veeva This press release contains forward-looking statements about Veeva's products and services and the expected benefits of using our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this press release, and we have no obligation to update such statements. There are numerous risks that may adversely affect our results, including the risks and uncertainties disclosed in our report on Form 10-Q for the fiscal year ended July 31, 2026, which you can find here (a summary of the risks that may affect our business is on pages 33 and 34), and in our subsequent reports filed with the SEC, which you can access through sec.gov.

Belgian drugmaker UCB raises 2026 outlook on two key drugs UCB now expects sales growth of more than 20% this year, helped by strong demand for Bimzelx and Cimzia, and its shares jumped 13%. MARKETWIRE 22 October 2026at 12:59

Newsletter. / | / | / | Europe has the science on Alzheimer's disease. Now it needs a plan to deliver it | | Read the full article here. | / | As new diagnostic tests and treatments have changed what an Alzheimer's disease diagnosis can mean, patients, doctors, MEPs and industry warn that limited funding, health systems lagging behind innovation and missing political will could still leave people waiting. | Read more | | | / / | / | / | What is the impact of overweight and obesity in Germany? | | A recent report by the Office of Health Economics, commissioned by EFPIA, shows that elevated BMI is associated with 278,000 deaths and almost 8 million years of healthy life lost annually across eight European countries. The economic costs are equally significant, accounting for 0.6% to 1.4% of national GDP. Germany has the largest total annual burden, at €55.2 billion. Find out more in the report and the infographic. | | / / | / | / | The IPHA Podcast: Safe Hearts, Stronger Nations: Turning EU Ambition into Irish Action | | Hosted by Professor Michal Vrablik, Professor of Internal Medicine at Charles University and an architect of the Czech National Cardiovascular Plan, and David Kelly, Operations Manager at Global Heart Hub, Chair of Heart and Stroke Voice Ireland, and a congenital heart valve disease patient, the discussion moves between policy and lived experience. Listen to the podcast here. | | / / | / | / | IHI Forum 2026 - Translating research into long-term impact | How can research partnerships deliver lasting impact for patients and Europe? Watch the video message from Jean-Christophe Tellier, Chief Executive Officer of UCB, presented at the IHI Forum 2026. | | / | / | / | / | Events | | / | 11 NOV 2026 | / | / | Health Means Wealth conference Prague, Czech Republic The Health Means Wealth conference will explore how investing in health and innovation can strengthen health system... Learn more | | | / | 17 NOV 2026 | / | / | Europe's Life Sciences Competitiveness Agenda - Innovation, investment and global... Hybrid Organised by Rapporteur, this event will explore how Europe can strengthen its life sciences competitiveness and improve... Learn more | | | / / | / | About the EFPIA newsletter The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world. | | / |